Compare
Gilead Sciences vs Neurocrine Biosciences (GILD vs NBIX)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Gilead Sciences (GILD) returned +36.1% and Neurocrine Biosciences (NBIX) +7.1%; so far this year the figures are +36.0% and +16.1%.
Gilead Sciences is the larger company by market value, about 12.4 times the size of Neurocrine Biosciences.
Revenue grew +6.5% at GILD and +38.0% at NBIX over the last year.
GILD yields 1.95%. NBIX pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| GILD | NBIX | |
|---|---|---|
| Price | $166.89 | $164.63 |
| 1-day | -0.41% | +3.05% |
| YTD | +35.97% | +16.08% |
| 1 year | +36.15% | +7.08% |
| 3 years | +108.12% | +47.60% |
| Market cap | $207.0B | $16.7B |
| P/E | — | 24.4 |
| P/S | 6.68 | 4.50 |
| P/B | 15.87 | 4.30 |
| Revenue growth | +6.50% | +38.00% |
| EPS growth | -149.00% | +61.20% |
| Gross margin % | 79.9 | 97.8 |
| Net margin % | -12.5 | 19.0 |
| ROE % | -29.6 | 18.1 |
| Debt / equity | 2.01 | 0.00 |
| FCF yield % | 6.7 | 6.2 |
| Dividend yield % | 1.95 | — |
| Beta | 0.37 | 0.64 |
| RSI (14) | 60.2 | 69.4 |
| Technical rating |